Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
BACKGROUND
The transdermal patch (20 microg ethinylestradiol+150 microg norelgestromin daily) and the vaginal ring (15 microg ethinylestradiol+120 microg etonogestrel daily) are new contraceptives, designed to deliver a low dose of hormones, suggesting a low exposure. However, few data are available about their risk of venous thrombosis. The objective was to investigate the effect of the patch, the ring, and an oral contraceptive (30 microg ethinylestradiol+150 microg levonorgestrel daily) on activated protein C sensitivity ratio (APC-sr) and on sex hormone-binding globulin (SHBG) levels in plasma.


METHODS
After a two month wash-out, 13 volunteers were randomly assigned to either the patch followed by the oral contraceptive or vice versa, or the ring followed by the oral contraceptive or vice versa. All treatments lasted two cycles and were separated by a wash-out of two cycles. APC-sr and SHBG levels were determined on day 18-21 of the second cycle of the wash-out and of each treatment period.


RESULTS
Compared to the oral contraceptive, both the patch and the ring led to higher APC resistance (mean difference APC-sr 1.1; 95% CI 0.67-1.52 and 0.55; 95% CI 0.11-1.00, respectively) and higher SHBG levels (mean difference 210 nmol/l; 95% CI 134-286 and 148 nmol/l; 95% CI 48-248, respectively).


CONCLUSIONS
The activity of the protein C system in plasma was impaired more by contraceptive patch and vaginal ring than by an oral contraceptive containing the second generation progestagen levonorgestrel.
Fleischer
K
K
Department of Gynaecology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. katflei@xs4all.nl
van Vliet
H A
HA
Rosendaal
F R
FR
Rosing
J
J
Tchaikovski
S
S
Helmerhorst
F M
FM
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D003274:Contraceptive Devices, Female / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D011486:Protein C / Q000378:metabolism*; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism*; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology; D055815:Young Adult
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D011486:Protein C; D012738:Sex Hormone-Binding Globulin